Summary
3M Company announced a significant acquisition, entering into a Stock Purchase Agreement to acquire Acelity L.P. Inc. for approximately $4.4452 billion in cash. Including assumed debt, the enterprise value of this transaction is approximately $6.725 billion. This move is expected to bolster 3M's portfolio, though the company has outlined the typical closing conditions, including regulatory approvals like HSR, and potential termination rights for both parties. The deal also includes customary representations and warranties, with provisions for operating the acquired business in the ordinary course until closing. Investors should note that this acquisition is subject to several closing conditions, including antitrust clearances, and the agreement can be terminated under specific circumstances, such as failure to close by a certain date or significant breaches. 3M has also provided a forward-looking statement section detailing potential risks and uncertainties associated with the transaction, including integration challenges, regulatory hurdles, and market conditions. The company released this information via a press release on May 2, 2019.
Key Highlights
- 13M Company entered into a Stock Purchase Agreement to acquire Acelity L.P. Inc. for approximately $4.4452 billion in cash.
- 2The total enterprise value of the acquisition, including assumed debt, is approximately $6.725 billion.
- 3The acquisition is subject to customary closing conditions, including expiration of antitrust waiting periods (e.g., Hart-Scott-Rodino) and other governmental approvals.
- 4The agreement includes provisions for termination under specific circumstances, such as failure to close by February 1, 2020 (extendable to May 1, 2020) or non-appealable orders prohibiting the transaction.
- 5The Stock Purchase Agreement contains standard representations, warranties, and covenants for both parties.
- 63M has included a forward-looking statements section detailing potential risks and uncertainties related to the transaction, such as integration challenges and regulatory approvals.